Compare ONTF & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONTF | HELP |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 281.4M |
| IPO Year | 2021 | N/A |
| Metric | ONTF | HELP |
|---|---|---|
| Price | $8.11 | $4.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.10 | ★ $95.00 |
| AVG Volume (30 Days) | 599.1K | ★ 1.2M |
| Earning Date | 05-06-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $139,312,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.35 | $4.29 |
| 52 Week High | $8.11 | $8.55 |
| Indicator | ONTF | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 44.86 |
| Support Level | $7.84 | $4.47 |
| Resistance Level | N/A | $5.02 |
| Average True Range (ATR) | 0.02 | 0.33 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 88.89 | 66.04 |
ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others. Geographically, the company derives maximum revenue from United States, and also has its presence in EMEA and Other Countries.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.